Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOKE: Ex Vivo Corneal Cross-Linking for Keratoconus
NCT04584125Not yet recruiting
- Start
- Jan 2027
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of Flavin mononucleotide in keratoconus (2 arms). Primary endpoint: Keratometric astigmatism at 130 weeks. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
Flavin mononucleotide
03
Conditions
keratoconus
Beyond the preview
Go deeper on NCT04584125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04584125.